Saragoça M A, Portela J E, Plavnik F, Ventura R P, Lotaif L D, Ramos O L
Instituto Paulista de Estudos e Pesquisas em Nefrologia e Hipertensão Arterial (IPEPENHI)-Escola Paulista de Medicina, SP.
Arq Bras Cardiol. 1992 Mar;58(3):233-6.
Evaluate the efficacy and tolerability of isradipine, a new dihydropyridine calcium antagonist in the therapy of outpatients hypertensive crisis.
Twenty seven patients with mean age of 37.2 +/- 2.5 years (ages ranging from 18 to 59 years old) of different races (14 white, 13 not white); 15 men and 12 women, with diastolic blood pressure over 130 mmHg and without signs of recent target organ damage were studied. The patients were divided in three groups according to the used dosage of Isradipine tablets by sublingual route. Group I (n = 10): 1.25 mg; Group II (n = 10): 2.5 mg and Group III (n = 7): 5.0 mg. Arterial blood pressure levels and heart rate were determined before the drug administration and every 30 minutes until 120 minutes after dosing.
Mean arterial blood pressure (MABP) decrease significantly in all patients from 153.43 +/- 4.3 to 124.0 +/- 2.3 mmHg after 60 minutes and to 118.0 +/- 2.1 mmHg after 120 minutes (p < 0.001). Heart rate did not show significant changes with the drug. Clinical significant side effects were not observed. The comparative analysis of MABP curves did not show significant differences among the groups I, II and III. However, a tendency of a greater decrease in MABP was observed in the patients of group III.
Isradipine tablets in the dosages of 1.25, 2.5 and 5.0 mg by sublingual route is effective and well tolerated in the treatment of ambulatorial patients with hypertensive crisis.
评估新型二氢吡啶类钙拮抗剂伊拉地平治疗门诊高血压急症的疗效和耐受性。
研究了27例平均年龄为37.2±2.5岁（年龄范围为18至59岁）、不同种族（14例白人，13例非白人）的患者；其中15例男性，12例女性，舒张压超过130 mmHg且近期无靶器官损害迹象。根据伊拉地平片舌下给药的剂量将患者分为三组。第一组（n = 10）：1.25 mg；第二组（n = 10）：2.5 mg；第三组（n = 7）：5.0 mg。在给药前以及给药后每30分钟直至120分钟测定动脉血压水平和心率。
所有患者的平均动脉血压（MABP）在60分钟后从153.43±4.3 mmHg显著降至124.0±2.3 mmHg，120分钟后降至118.0±2.1 mmHg（p < 0.001）。心率未随药物出现显著变化。未观察到具有临床意义的副作用。MABP曲线的比较分析显示，第一组、第二组和第三组之间无显著差异。然而，第三组患者的MABP有更大下降的趋势。
伊拉地平片1.25、2.5和5.0 mg舌下给药剂量在治疗门诊高血压急症患者中有效且耐受性良好。
